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Editor's Note:
The scope of nephrology is, happily, continually expanding. Kidney International is acutely aware of its responsibility, as the official journal of
the International Society of Nephrology, to serve the needs of the entire spectrum of renal clinicians and investigators.
For some years, the invited editorials appearing at the beginning of each month's issue of Kidney International, together with Nephrology Forum,
have served the needs of our constituencies. But clinical nephrology has grown explosively. Moreover, the translation of laboratory information
into clinically useful arguments is becoming increasingly short.
For that reason, beginning with this issue of Kidney International, we introduce a new series entitled Perspectives in Clinical Nephrology. Both
PCN and Nephrology Forum will be directed primarily toward clinicians and/or clinical investigators whose major focus of inquiry is the patient.
Like Nephrology Forum, PCN will attempt to translate, as rapidly as possible, advances made in the laboratory into constructs that help analyze
the physiology and pat hophysiology of disease. In turn, this construct will allow us to orient the Editorial Reviews, to an increasing degree, toward
issues focused more on laboratory inquiry.
The Editors hope that this new series will, to an increasing degree, serve the needs of all of the readership of Kidney International.
T.E. ANDREOLI
FOR THE EDITORS
PERSPECTIVES IN CLINICAL NEPHROLOGY
Anti-neutrophil cytoplasmic antibodies: Current diagnostic and
pathophysiological potential
Rapidly progressive glomerulonephritis (RPGN) is a clinical
syndrome characterized by rapid deterioration of renal function
occurring within days or weeks together with signs of glomer-
ulonephritis, that is, proteinuna and hematuria with cellular
casts. The syndrome is, in many cases, histopathologically
manifested as fibrinoid necrosis of the capillary wall with
extracapillary proliferation and crescent formation [1]. This
so-called necrotizing crescentic glomerulonephritis (NCGN) is
seen in 5 to 15% of renal biopsies in most series [1—3]. Although
it is infrequent, the importance of the condition is illustrated by
the fact that most cases of NCGN, if left untreated, develop
renal failure within days or weeks [1]. Based on immunohisto-
pathology NCGN can be subdivided into three distinct catego-
ries. The first one, occurring in 2 to 20% of the cases and
characterized by linear staining of the glomerular capillary wall
for immunoglobulin and complement, has classically been de-
scribed as anti-glomerular basement membrane (GBM) disease.
It is associated with autoantibodies to structural antigens of the
GBM, in particular to the first globular noncollagen domain of
collagen type IV [4]. The antibodies are considered of patho-
genetic significance. The second category, comprising 15 to
50%ofcases, is characterized by granular deposits of immuno-
globulin and complement suggesting that immune complexes
are pathogenetically involved. This type occurs in conjunction
with systemic autoimmune diseases such as lupus erythemato-
sus, in cases of post-infectious glomerulonephritis, IgA ne-
phropathy or Henoch-Schönlein purpura, or as an idiopathic
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variety. The third group of NCGN, occurring in 40 to 80%,
demonstrates only a few or no immune deposits and is desig-
nated as pauci-immune NCGN [1—3, 5, 6]. Pauci-immune
NCGN occurs as part of Wegener's granulomatosis (WG) or
related conditions, or without systemic vasculitis (idiopathic
NCGN). The pathophysiology of this pauci-immune type of
NCGN has not been elucidated. Within the last decade, how-
ever, it has been recognized that the condition is associated
with autoantibodies to cytoplasmic components of neutrophils
(anti-neutrophil cytoplasmic antibodies or ANCA).
ANCA were first described in 1982 by Davies et al in a few
patients with segmental necrotizing glomerulonephritis [71.
Only in 1985 did it become apparent that ANCA are a sensitive
and specific marker for Wegener's granulomatosis (WG) [8].
Later on, ANCA were described in patients with microscopic
polyarteritis [9]. Falk and Jennette, in 1988, showed that ANCA
are also associated with the idiopathic form of pauci-immune
NCGN [10]. These data have now been confirmed by many
groups and support the view that ANCA-associated glomerulo-
nephritis and vasculitis is, indeed, a distinct disease category. A
number of studies, in addition, have suggested that ANCA are
involved in the pathophysiology of the aforementioned disor-
ders. As ANCA, however, have recently also been detected in
a wide range of inflammatory and infectious conditions, a
critical reappraisal of the diagnostic significance of ANCA-
testing seems justified.
In this review we will evaluate the current state of ANCA-
testing as well as elaborate on the pathophysiological role of the
autoantibodies in necrotizing glomerulonephritis and vasculitis.
Data presented recently at the Fifth International Workshop on
ANCA, held in Cambridge, United Kingdom, will be included
[11]. As such, it adds to previous reviews on ANCA that were
published following the Second [12], Third [13], and Fourth [14]
Workshops on ANCA.
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ANCA: A class of different autoantibodies
ANCA as detected by indirect immunofluorescence
Fig. 1. Staining of ethanol fixed neutrophils by indirect immunofluo-
rescence by sera producing: (a) a characteristic cytoplasmic staining
pattern with accentuation of the fluorescence intensity in the area
within the nuclear lobes (c-ANCA, top); (b) a perinuclear staining
pattern (p-ANCA, middle); (c) an atypical cytoplasmic staining pattern
showing a more diffuse finely speckled fluorescence throughout the
cytoplasm (bottom).
ANCA are routinely detected by indirect immunofluores-
cence (hF) on ethanol fixed neutrophils [15]. At least three
different patterns of fluorescence can be distinguished (Fig. 1):
a cytoplasmic pattern with accentuation of the fluorescence
intensity in the area within the nuclear lobes (cytoplasmic or
c-ANCA), a perinuclear pattern (p-ANCA), and a more diffuse
cytoplasmic staining pattern (atypical ANCA). The first pattern
has been recognized as a characteristic staining pattern pro-
duced by the sera of most patients with WG [8, 16], but also of
some 50% of patients with microscopic polyangiitis/arteritis and
a minority of patients with other necrotizing vasculitides or
idiopathic NCGN [reviewed in 17]. P-ANCA were originally
described by Faik and Jennette [10] in patients with idiopathic
and/or vasculitis-associated NCGN. Further studies showed
that the p-ANCA pattern can be produced also by sera from
patients with vasculitis without renal involvement, and patients
with inflammatory bowel diseases, autoimmune liver diseases,
infectious diseases such as HIV infection, and rheumatic dis-
orders as systemic lupus erythematosus (SLE) and rheumatoid
arthritis [17, 18]. The perinuclear pattern cannot always be
distinguished from a nuclear staining pattern. Thus, discrimina-
tion between antinuclear antibodies (ANA) and p-ANCA is not
possible in most sera that are ANA-positive when isolated
ethanol-fixed neutrophils are used as a substrate. In fact,
antibodies reacting with nuclei of granulocytes only, and not
with that of other substrates, have been detected in patients
with rheumatoid arthritis long before ANCA had been de-
scribed, and were named granulocyte-specific antinuclear anti-
bodies (GS-ANA) [19, 20]. Recent studies, however, have
shown that the p-ANCA pattern produced by sera from patients
with NCGN is an artifact of ethanol fixation [21]. When
neutrophils are fixed with a cross-linking fixative such as
paraformaldehyde, those sera produce a cytoplasmic staining
pattern [21, 22] whereas ANA-positive sera still display a
nuclear staining. As will be discussed below, a number of
antigens recognized by ANCA, such as myeloperoxidase, are
highly cationic proteins. During ethanol fixation those cationic
proteins move to the negatively charged nuclear membrane [22]
which explains the perinuclear fluorescence pattern. The third
pattern, an atypical cytoplasmic fluorescence staining, has not
been linked to particular antigens nor to specific disease entities
until now.
What do we learn from these data? First, detection of ANCA
by hF should be performed in a standardized way by highly
skilled technicians in order to get reproducible results.
Cytospins of the buffy coat are preferentially used as a substrate
since the simultaneous presence of lymphocytes and neutro-
phils in the preparation allows the distinction between ANCA,
which are myeloid specific, and ANA although the presence of
ANCA cannot be excluded in ANA-positive sera. Besides
ethanol fixation, paraformaldehyde-fixed preparations may be
used since some sera are positive for ANCA on the latter
substrate and negative on the former [23]. A recent collabora-
tive European study has shown that ANCA-testing according to
a standard protocol using ethanol-fixed leukocytes results in
very low inter-laboratory variance [24]. Secondly, a positive
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ANCA-test by hF is in itself not diagnostic for a particular
condition but should be followed by antigen-specific assays.
ANCA: Their target antigens
Proteinase 3. The antigen recognized by most c-ANCA
positive sera has been identified as proteinase 3, a third serine
protease from the azurophilic granules of neutrophils different
from elastase and cathepsin G, the other two serine proteases
from these granules [25—27],
Proteinase 3 has been cloned and was shown to be a 29 kD
glycoprotein of 228 amino acids [281 that is identical to p29b, a
recently described antibiotic protein from human neutrophils
[29], and myeloblastin, a growth-promoting protein from my-
eloid cells [30]. The enzyme is slightly cationic, has proteolytic
activity as measured on several substrates [31], and is physio-
logically inhibited by a1-antitrypsin [32]. Proteinase 3-a1-anti-
trypsin complexes can, indeed, be detected in inflammatory
fluids [32]. A 47 kD glycoprotein is also recognized by poly-
clonal and monoclonal antibodies that react with the 29 kD
molecule as shown by Goldschmeding et a! [25]. It has recently
been demonstrated that this 47 kD moiety has senne protease
activity and, probably, represents a post-transcriptional modi-
fication of the cDNA encoding for myeloblastin/proteinase 3
[33]. Human antibodies to proteinase 3 appear to recognize
conformational determinants on the molecule [34]. The
epitope(s) in question are localized at or near the catalytic
domain of the molecule as human autoantibodies to proteinase
3 interfere with the inactivation of the enzyme by a1-antitrypsin
[35]. In most cases binding of the antibody to proteinase 3 not
only inhibits inactivation of the molecule by anti-proteases but
also results in inactivation of proteinase 3 itself; in some
instances, however, enzymatic activity is retained [35].
Proteinase 3 is localized in the azurophilic or a-granules from
myeloid cells. It is present both in monocytes and granulocytes
and appears early in mono-myeloid differentiation [36, 37].
Proteinase 3 is released from activated neutrophils by a process
involving fusion of the membrane of azurophiic granules with
the plasmamembrane [38]. When neutrophils are primed, that
is, pre-activated with a low dose of TNFa (100 pg/mI), protein-
ase 3 appears at the cell membrane being available for interac-
tion with its cognate antibody [39]. In vivo, circulating neutro-
phils showing membrane expression of proteinase 3 have been
detected in conditions as septic shock and also in patients with
active WG [40]. Interestingly, recent studies by Mayet et a!
have shown that proteinase 3 can also be expressed in a renal
carcinoma cell line [41] and, more importantly, in cultured
human endothelial cells from umbilical veins [42]. In cytokine-
treated endothelial cells proteinase 3 moves towards the cell
membrane suggesting that the antigen may in vivo be a direct
target for circulating autoantibodies [42]. Proteinase 3 can be
purified from neutrophil granules by dye-ligand affinity and
ion-exchange chromatography [43], by immunoaffinity chroma-
tography [44], or by high pressure liquid chromatography [45].
Purified protein can be used in ELISA systems for quantitation
of specific antibodies [24]. Anti-proteinase 3 antibodies can also
be detected by a capture ELISA in which a monoclonal
antibody selects the relevant antigen from a crude extract of
a-granules [3, 25].
Myeloperoxidase (MPO). Following the description of
c-ANCA as a marker for WU several groups observed that a
Table 1. Neutrophil granule constituents
Class of
constituent Azurophilic granules Specific granules
Microbial enzymes myeloperoxidase
lysozyme lysozyme
Serine proteinases elastase
cathepsin 0
proteinase 3
azurocidin
Metalloproteinases collagenase
gelatinase
Acid hydrolases N-acetyl-p-
glucosaminidase
cathepsin B
cathepsin D
13-glucuronidase
/3-glycerophosphatase
a-mannosidase
Other defensins lactoferrin
vitamin B 12-binding
protein
number of sera from patients suspected of vasculitis produced a
perinuclear fluorescence pattern on ethanol-fixed neutrophils.
During the first international workshop on ANCA in 1988
Goldschmeding et al [46] reported that many of those sera
contained antibodies to MPO and, incidentally, to elastase, and
Falk and Jennette also mentioned MPO as the relevant antigen
[47, 10]. Based on the latter data p-ANCA became almost
synonymous for anti-MPO, which, as already has been dis-
cussed, is not true. In fact, many p-ANCA positive sera are
directed against antigens different from MPO, whereas some
sera with anti-MPO antibodies produce a cytoplasmic staining
pattern on ethanol-fixed neutrophils [48, 49]. MPO is a highly
cationic protein (p1 11.0) with a molecular wt of 146 kD, and
consists of two chains. The enzyme plays a critical role in the
generation of reactive oxygen species [SO]. By immunoprecip-
itation at least two bands of approximately 60 and 42 kD,
representing a complete and a partly degraded single chain, are
recognized both by monoclonal and human polyclonal antibod-
ies [25]. Western blotting studies demonstrate that human
anti-MPO antibodies recognize native MPO but not denatured
MPO suggesting that confirmational epitopes are involved [51—
53]. The human autoimmune response to MPO is directed
against multiple epitopes as demonstrated by inhibition studies
using anti-MPO positive sera and a set of different monoclonal
antibodies [541. The relevant epitopes have not yet been defined
but most anti-MPO positive sera do not seem to inactivate the
enzymatic activity of the molecule [51, 52]. Studies performed
in mice have demonstrated the occurrence of natural anti-MPO
antibodies of the IgM-isotype, some of which are polyreactive
[55J. Autoantibodies to MPO have also been demonstrated in
Brown Norway rats treated with mercuric chloride which
induces a T-cell-dependent polyclonal B-cell activation [53].
These data suggest that also in humans low-affinity 1gM-class
antibodies are present at the germ line which may develop into
high-affinity IgG-class anti-MPO by antigen-driven selection in
the presence of their cognate T cells. In this respect, cross-
reactivity or homology between MPO and other proteins may
be relevant. As such, the homology demonstrated between
MPO and heat shock proteins is of interest [561.
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For the detection of anti-MPO antibodies commercially avail-
able MPO can be used in ELISA systems. Those preparations,
however, may contain impurities, in particular lactoferrin [57].
Alternatively, a capture ELISA can be used [3, 25, 48].
Other antigens. Many sera that produce a perinuclear or
atypical cytoplasmic staining pattern on ethanol fixed neutro-
phils do not contain antibodies to MPO or proteinase 3 as tested
by antigen-specific assays. It has now been recognized that a
number of these sera contain antibodies to defined granular
constituents of neutrophils (Table 1). In particular, autoantibod-
ies have been demonstrated to lactoferrin [23, 58—63] and
lysozyme [64], which are constituents of the specific granules,
to elastase [25, 65] and cathepsin G [66], the two other serine
proteases that are present in the azurophiic granules, and to
f3-glucuronidase, another constituent of those granules [67]. In
addition, autoantibodies have been detected that are directed
against cytosolic components of neutrophils, in particular to
alpha-enolase [68]. The presence of these autoantibodies have
been demonstrated in most of the cases by ELISA, and not by
additional Western blotting or immunoprecipitation. Detection
by ELISA did not always parallel detection by hF on ethanol-
or formalin-fixed neutrophils. Their clinical associations will be
discussed below.
ANCA: Diagnostic significance
Although ANCA were first described in a few patients with
necrotizing glomerulonephritis [7], large interest in the autoanti-
bodies arose from their presence in WG [8]. Numerous studies
published in recent years, however, have shown that ANCA are
far from specific for WG, and have challenged the diagnostic
potential of the autoantibodies. These sometimes conflicting
data ask for a critical reappraisal of the clinical value of ANCA
testing.
Wegener's granulomatosis
Following the original description of ANCA in WG [8] many
studies have confirmed the sensitivity of c-ANCA or anti-
proteinase 3 for a diagnosis of WG. Three major studies
comprising more than 200 patients have found a sensitivity of
90% for so-called extended WG characterized by the triad of
granulomatous inflammation of the respiratory tract, systemic
vasculitis, and necrotizing crescentic glomerulonephritis [16,
69, 70]. The sensitivity of anti-proteinase 3 for limited WG, that
is, disease manifestations without obvious renal involvement,
amounted to 75% [17]. It should be mentioned that these data
concern patients with active disease only. During remission
c-ANCA were detected in a far lower percentage of the pa-
tients. Generally, the presence of c-ANCA as detected by hF
corresponded with their presence as detected by proteinase
3-specific ELISA [3, 691. Many other studies dealing with
smaller numbers of patients have confirmed these findings
[reviewed in 71]. The association between anti-proteinase 3 and
WG is, however, not absolute: some patients with active
(generalized) WG are ANCA-negative. Most of the patients
who are negative for anti-proteinase 3 have, however, antibod-
ies to MPO or leukocyte elastase [10, 48, 65, 71].
The specificity of anti-proteinase 3 for active WG has been
found as high as 98% [16, 69, 71] when sera were studied from
patients with a wide variety of renal, autoimmune, vasculitic,
infectious, or lymphoprolilerative disorders. It should, how-
Table 2. Traditional classification of systemic idiopathic vasculitides
I. Affecting predominantly large- and medium-sized blood vessels
1. Takayasu's arteritis
2. Giant cell arteritis/temporal arteritis
II. Affecting predominantly medium- and small-sized blood vessels
1. Classic polyarteritis nodosa
2. Churg-Strauss syndrome
3. Wegener's granulomatosis
4. Polyangiitis overlap syndrome
III. Affecting predominantly small blood vessels
1. Microscopic polyarteritis
2. Henoch-Schdnlein purpura
ever, be realized that anti-proteinase 3 antibodies are detected
in patients with overlapping symptoms of WG and other forms
of vasculitis, and in some patients with idiopathic necrotizing
glomerulonephritis without systemic involvement [3, 48, 69,
72]. Some of these patients will evolve into definite (extended)
WG as classified according to the ACR criteria [73] or according
to the definition recently proposed by an international study
group on vasculitis [74]. Very recently, anti-proteinase 3 anti-
bodies have been described in patients with invasive amoebiasis
[75] and in patients with thyroid disease treated with propyl-
thiouracil [76]. The latter patients simultaneously developed
antibodies to other myeloid enzymes such as MPO and elastase
together with clinical signs of vasculitis. These findings may
suggest that the thiol group of the drug is involved in the
induction of this polyclonal autoimmune reaction.
As mentioned before, the prevalence of c-ANCAIanti-pro-
teinase 3 in patients with active WG is far higher than that in
inactive disease. Various longitudinal studies have shown that
titers of ANCA rise prior to a relapse of WG [16, 77]. The rise
proved very sensitive for an ensuing relapse and was detectable
a mean of 49 days (range 9 to 106 days) before the moment of
clinical relapse [161. Based on these findings, a prospective
study was undertaken on 58 patients with WG to test whether
treatment based on changes in c-ANCA titer could prevent the
occurrence of relapses [78]. In this study blood samples were
tested every month for ANCA titer. Over an observation period
of 24 months titers of ANCA rose in 20 patients. None of the
nine patients who were randomized for treatment at the time
ANCA titer had risen (without having major clinical signs at
that moment) relapsed. In contrast, nine of the 11 patients who
were not treated at that moment, finally developed a relapse.
Those latter patients used more immunosuppressives and cor-
ticosteroids than the patients who were treated immediately at
the time ANCA titer had risen. These data have been chal-
lenged by a recent report from the NIH group [79] demonstrat-
ing a rather poor correlation between changes in ANCA titer
and disease activity of WG. A closer look at their data [80],
however, shows that all 17 patients from the NIH study who
were either in remission or had stable disease developed
relapses that were preceded (24%) or parallelled (76%) by an
increase of c-ANCA titer. Changing titers not corresponding to
disease activity mainly occurred in patients with (persistently)
active disease. Persistingly or intermittently positive tests for
ANCA in patients who come into remission have been shown to
be a considerable risk factor for an ensuing relapse (RR 20
compared to patients who are persistently ANCA-negative after
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Table 3. Classification of the idiopathic vasculitides as proposed by
an international study group at the Chapel Hill Consensus
Conference on the Nomenclature ofSystemic Vasculitis (adapted
from [74])
I. Large vessel vasculitis
1. Giant cell (temporal) arteritis
2. Takayasu arteritis
II. Medium-sized vessel vasculitis
1. Polyarteritis nodosa
2. Kawasaki disease
HI. Small vessel vasculitis
1. Wegener's granulomatosis
2. Churg-Strauss syndrome
3. Microscopic polyangiitis
4. Henoch Schönlein purpura
5. Essential cryoglobulinemic vasculitis
6. Cutaneous leukocytoclastic angiitis
remission) [81]. Interestingly, persistence of ANCA is associ-
ated with certain HLA class II genes, in particular the DQw7,
DR4 haplotype [82], suggesting that genetic factors are involved
in the autoimmune response.
In conclusion, the presence of anti-proteinase 3 strongly
suggests a diagnosis of WG although the association is not
absolute. Increasing titers of the autoantibodies should alert the
clinician to the possibility of an ensuing relapse.
Other idiopathic necrotizing vasculitides including idiopathic
pauci-immune NCGN
The necrotizing vasculitides are traditionally grouped accord-
ing to the size of the vessels involved and the histopathology of
the inflammatory process (Table 2). Classification criteria based
mainly on clinical signs and symptoms have been published by
the American College of Rheumatologists (ACR) [83]. Although
useful in clinical practice, these criteria do not strictly define the
disease in question. Using these criteria, various degrees of
sensitivity and specificity are obtained. As the criteria are not
mutually exclusive one particular patient may be classified as
having two or more disease entities. Recently, an international
study group has newly defined the several vasculitides based,
generally, on histopathologic findings (Table 3) [74]. The main
difference with the traditional classification (Table 2) lies in the
distinction between medium sized and small vessel vasculitis.
In medium sized (and large) vessel vasculitis vessels smaller
than arteries are not involved, whereas in small vessel vasculitis
large vessels may be involved as well. A diagnosis of polyarteri-
tis nodosa requires the presence of necrotizing arteritis but is
excluded when arterioles, capillaries or venules are involved as
well. In the latter situation the diagnosis probably will be
microscopic polyangiitis according to the Chapel Hill confer-
ence [74]. Classification criteria based on both clinical and
histopathologic findings stifi have to be established by this
group. At present, one should realize that the same name may
be used for different diseases and vice versa. In addition, in
clinical practice many patients present with overlapping fea-
tures of different vasculitides and cannot be classified within
one category. Data on prevalences of ANCA in the various
vasculitides should be valued with these considerations in
mind.
Table 4 Disease associations of anti-proteinase 3 antibodies and
anti-myeloperoxidase antibodies
Sensitivity of
Anti-proteinase 3 Anti-myeloperoxidase
Disease entity % %
Wegener's granulomatosis 85 10
Microscopic polyangiitis 45 45
Idiopathic crescentic 25 65
glomerulonephritis
Churg-Strauss syndrome 10 60
Polyartentis nodosa 5 15
Data are derived from the references cited in the text.
Microscopic polyarteritis or angiitis (MPA). This is charac-
terized by (pauci-immune) necrotizing vasculitis involving small
sized vessels [84]. A pulmonary-renal syndrome consisting of
NCGN in combination with pulmonary capillaritis is not un-
common. Most patients with MPA are ANCA-positive, either
with specificity for proteinase 3 or for MPO [85]. There seems
to be no clear distinction between patients positive for anti-
proteinase 3 or anti-MPO, although a number of anti-proteinase
3 positive patients develop histologically confirmed WG during
the course of their disease (own observations). The relation
between titers of ANCA and disease activity has not been
studied systematically in MPA.
Idiopathic pauci-immune NCGN. This can be considered as
a renal limited form of MPA. Most patients with this latter
disorder are positive for anti-MPO, the remaining generally
being positive for anti-proteinase 3 [3, 10]. At a closer look,
however, many patients with idiopathic NCGN have constitu-
tional symptoms together with signs of systemic involvement
such as arthralgias, purpura and/or otorhinolaryngologic symp-
toms. As such, the distinction between WG, MPA, and idio-
pathic NCGN is far from absolute.
Anti-GBM disease. Interestingly, anti-MPO antibodies also
have been detected in 30 to 40% of patients with anti-GBM
disease [86—88]. Patients having both anti-MPO and anti-GBM
antibodies are considerably older than patients with anti-GBM
antibodies only. In some of these patients clinical and patho-
logical data suggest associated systemic vasculitis, and among
these patients recovery of renal function has been reported
despite their initial need for hemodialysis [871. Whether ANCA
in anti-GBM disease develop concomitantly with anti-GBM
antibodies, possibly as a result of polyclonal activation, is
presently not clear.
Churg Strauss syndrome. Characterized by (a history of)
asthma and hypereosinophilia in conjunction with systemic
vasculitis with or without renal involvement, Churg Strauss
syndrome is associated with anti-MPO antibodies [89]. Com-
bining data from several studies the prevalence of anti-MPO in
this disorder may be estimated as 75% [72, 90]. Classical
polyarteritis nodosa (PAN) defined as necrotizing arteritis
involving medium sized arteries is ANCA-negative in the ma-
jority of the cases [72, 90]. In a large series from France [90]
20% of the patients with PAN without hepatitis B virus infec-
tion were positive for ANCA, whereas 11% of those with HBV
infection were positive.
Kawasaki disease. The occurrence of ANCA in Kawasaki
disease, a mucocutaneous lymph node syndrome with, in a
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considerable number of cases, arteritis, in particular of the
coronary arteries, has not been definitely established. Acute
sera demonstrate positive homogeneous cytoplasmic staining in
23% of the patients possibly due to 1gM-class antibodies di-
rected to cathepsin G [91]. Large vessel vasculitides such as
Takayasu arteritis [92] and temporal arteritis [65, 93] generally
are ANCA-negative. Finally, the presence of ANCA, in partic-
ular of the IgA isotype, in Henoch SchOnlein purpura needs
consideration. Although these IgA-ANCA have been reported
in earlier studies [941, these data have not been confirmed by
other groups [95].
In summary, the presence of anti-proteinase 3 or anti-MPO
appears to characterize pauci-immune small vessel vasculitis of
different varieties frequently involving the kidney as well (Table
4).
Connective tissue diseases
Systemic lupus erythematosus. The prevalence of ANCA in
systemic lupus erythematosus (SLE) still is a matter of debate.
Antibodies to MPO [96, 97], elastase [97], and lactoferrin [61]
have been reported in this disease. Their prevalences differ
widely between several series, and their occurrence does not
seem to be associated with any particular disease subset.
Interestingly, anti-MPO have been detected in the sera of all six
patients with hydralazine induced lupus, in five of them in
combination with anti-elastase antibodies [98]. The simulta-
neous presence of specific ANCAs both in hydralazine induced
lupus and propyithiouracil induced vasculitis suggests a more
polyclonal immune activation in drug-induced autoimmunity
comparable to experimental mercuric chloride induced autoim-
mune disease in which anti-MPO antibodies are also detected
[53].
Rheumatoid arthritis. Granulocyte-specific ANA (GS-ANA)
[20, see before] have been described in rheumatoid arthritis
(RA) already in 1959 [99]. The detection of ANCA has evoked
renewed interest in those antibodies in RA. It has been shown
that, at least most of, GS-ANA are actually ANCA directed to
different antigens [23]. Among these lactoferrin is most promi-
nent. Anti-lactoferrin antibodies have been specifically associ-
ated with vasculitis in RA [58] and with Felty's syndrome [60],
although these data have not been confirmed by others [23,
100]. The latter studies actually suggest that ANCA in RA are a
secondary phenomenon related to disease duration.
Inflammatory bowel disease (IBD) and autoimmune
liver disease
The occurrence of ANCA in IBD, in particular in ulcerative
colitis, has raised interest in ANCA as a marker of ulcerative
colitis useful in the work-up of patients with diarrhea [101]. The
prevalence of ANCA in ulcerative colitis may be estimated as
50 to 80% compared to a 10 to 40% prevalence in Crohn's
disease [59, 102—104]. Titers of ANCA possibly follow disease
activity in ulcerative colitis but not in Crohn's disease [103—
105]. There is still no agreement on the antigens involved.
Cathepsin G as well as f3-glucuronidase have been proposed
[66, 67], but other studies suggest that the same antigens are
involved as in RA including lactoferrin [59]. ANCA have also
been described in a considerable number of patients with
primary sclerosing cholangitis, a hepatic disease of possible
autoimmune origin associated with IBD [106]. ANCA, how-
ever, were also found in 60 to 70% of patients with chronic
active hepatitis, and 35% of those with primary biliary cirrho-
sis. The antigens involved have only partly been characterized
[107].
Infectious diseases
ANCA, generally of undefined specificity, have been de-
scribed in HIV infection and mucoviscidosis with secondary
infection [108, 109]. As mentioned before, a recent report
described the occurrence of anti-proteinase 3 antibodies in
patients with amoebiasis [75]. In addition, incidental case
reports have mentioned the occurrence of ANCA in different
infectious and neoplastic disorders. These findings, although
unconfirmed, underscore that the detection of ANCA by hF
only has, at present, limited diagnostic value. The presence of
anti-proteinase 3 or anti-MPO in the relevant clinical context,
however, clearly points to one of the idiopathic forms of
necrotizing vasculitis or glomerulonephritis.
ANCA: Towards a role in the pathophysiology of
NCGN/vasculitis
The close association between anti-MPO and anti-proteinase
3 antibodies on the one hand and pauci-immune NCGN and
necrotizing vasculitis on the other hand suggests a pathophys-
iological role for the autoantibodies. There are, indeed, exper-
imental data that further substantiate a role for ANCA in the
pathophysiology of the aforementioned diseases.
Effect of ANCA on their target antigens
As discussed before binding of anti-proteinase 3 to its target
enzyme can inhibit the irreversible inactivation of the enzyme
by a1-antitrypsin, its natural inhibitor [35]. The inhibitory
activity differs between sera and is not directly related to the
amount of specific antibody [110]. In a longitudinal study it has
been shown that disease activity in patients with WG correlates
with the amount of inhibitory activity of the serum rather than
with the titer of the anti-proteinase 3 antibodies [110]. This
suggests that escape of the enzyme from its inactivation may
contribute to the inflammatory process. Although most anti-
proteinase 3 positive sera not only inhibit inactivation of
proteinase 3 but also its enzymatic activity [35], the reversible
antigen-antibody binding may be dissolved at the site of inflam-
mation allowing the enzyme to display its lytic activity.
The phenotypical expression of a1-antitrypsin is polymor-
phic: severely-, medium-, and non-deficient proteinase inhibitor
phenotypes can be distinguished. Interestingly, among 14 anti-
proteinase 3-positive patients with vasculitis, phenotypes defi-
cient for proteinase inhibitor activity were increased compared
to controls. Reversely, the prevalence of ANCA of diverse
specificities was remarkable amongst a population with the
severely deficient phenotype (20 out of 150) [111]. These data
suggest that deficient a1-antitrypsin activity is involved in the
induction of ANCA. Otherwise, this deficiency may contribute
to the expression of the lesions in ANCA-associated vasculitis.
Interaction between ANCA and endothelial cells
The antigens recognized by anti-MPO and anti-proteinase 3
are constituents of granules from myeloid cells and are thought
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to be specific for cells of the monomyeloid lineage. Recent
studies from Mayet et a! have demonstrated, however, that
proteinase 3 can be expressed in other cell types as well, in
particular in renal carcinoma cells [411 and in human endothelial
cells [42]. In the latter cells cytokine treatment either with
TNFa, IL-i, or IFN7, resulted in increased expression of
proteinase 3 with translocation of the enzyme to the cell
membrane. As such the antigen is available for interaction with
the autoantibody at sites of cytokine production. MPO and
proteinase 3 are cationic proteins with an isoelectric point of
11.0 and 7.8, respectively. These cationic proteins may bind to
anionic structures such as the glomerular basement membrane
(GBM) and the surface of endothelial cells. It has, indeed, been
shown that ANCA can bind to endothelial cells incubated with
MPO or proteinase 3 [112] although the interaction of protein-
ase 3 with endothelial cells has been disputed [113]. Under
these conditions, anti-MPO can, in vitro, induce complement
dependent endothelial cell lysis [112]. Although these in vitro
studies have demonstrated that ANCA can interact, directly or
indirectly, with endothelial cells, direct immunofluorescence
studies from lesional tissue have failed to show significant
deposition of IgG along the endothelium or the glomerular
capillary wall. Thus, the in vivo relevance of those in vitro
studies still has to be established.
Potential of ANCA to activate inflammatory cells
Falk et al were the first to demonstrate that ANCA can
activate neutrophils that are pre-treated ("primed") with low
dosage TNFa to the production of reactive oxygen species and
the release of lysosomal enzymes [114]. The mechanisms un-
derlying neutrophil activation by ANCA have only partly been
elucidated. Priming of neutrophils by TNFa results in the
expression of lysosomal enzymes such as MPO and proteinase
3 at the cell membrane [39]. Those pre-activated neutrophils
showing surface expression of proteinase 3 can be detected in
the peripheral blood in conditions as septic shock and at the
time of active disease in WG [40]. Binding of anti-proteinase 3
to primed neutrophils results in further activation. Falk et al
originally reported that activation can be induced by F(ab')2-
fragments of the antibodies [114]. Recent studies, however,
suggest that both F(ab)-binding and Fe-interaction are involved
[115, 116]. Blocking of the FcII receptor on neutrophils inhib-
ited activation [115]. The FcII receptor particularly interacts
with IgG2 and IgG3 subclasses of antibodies. Interestingly, sera
with relatively high levels of IgG3 subclass of ANCA preferen-
tially activate neutrophils [115], and renal exacerbations of WG
are associated with increases of the IgG3 subclass of ANCA
[1171 although IgGi and IgG4 subclasses of ANCA are present
as well [117]. The signal transduction pathway involved in
ANCA-mediated activation of neutrophils is still a matter of
debate [118—120]. Different pathways have been described
suggesting that protein kinase C (PKC) as well as Ca2-influx
are involved. The translocation of PKC to the cell membrane as
observed during ANCA-mediated activation [118] seems to be
the initial step, further steps are dependent on intracellular
calcium [1201. In vitro studies also have shown that primed
neutrophils in the presence of ANCA can lyse endothelial cells
in culture [121, 122]. In addition, it has been suggested that
ANCA can induce adhesion of neutrophils to monolayers of
cultured endothelial cells [123]. Considering these experiments
one should realize that isolation of neutrophils in itself may
result in some degree of activation depending on the methods of
isolation. This, apparently, may influence the results. Taken
together, ANCA of defined specificity have been shown to
activate primed neutrophils. The relevance of this phenomenon
for the pathophysiology of the necrotizing vasculitides needs
further study. In this respect, the capacity of ANCA to activate
primed neutrophils did not correlate with the amount of in situ
activated neutrophils present in renal biopsies from patients
with active WG [124].
T cell reactivity to ANCA -associated antigens
Besides neutrophils, inflammatory lesions of lung and kidney
in WG contain mononuclear infiltrates, frequently also in the
form of granulomas, which consist of monocytes and T cells,
the majority of which are CD4-positive [125, 126]. The presence
of these large cellular infiltrates, contrasting with the scanty
deposits of immunoglobulins [5, 6, 124], suggests that cell-
mediated immunity is involved in the pathogenesis of the
lesions as well. In agreement, elevated levels of soluble IL-2
receptors and increase in those levels preceeding major relapses
have been reported in patients with WG indicating the presence
of activated T cells [127, 128]. The target antigens of those
activated T cells are, however, not known. Microbial antigens,
in particular Staphylococcal antigens, might be involved as
chronic nasal carriage of Staphylococcus aureus has been
shown to be an important risk factor for the development of
relapses in patients with WG [81]. Otherwise, the target anti-
gens of ANCA, that is, proteinase 3 and MPO, are released at
the site of inflammation and could be targets for cell-mediated
immunity. Preliminary data have shown that lymphocytes iso-
lated from patients with WG proliferate in response to crude
neutrophil extracts containing proteinase 3 [129, 130]. We
recently demonstrated using in vitro lymphocyte proliferation
assays, that patients with WG positive for anti-proteinase 3
antibodies responded more frequently and stronger to protein-
ase 3 than controls [131]. However, 33% of healthy controls
also reacted in vitro to proteinase 3, whereas 35% of patients
with anti-proteinase 3 antibodies did not show in vitro T cell
reactivity to this autoantigen. Thus, the pathophysiological role
of (autoreactive) T cells in systemic vasculitis awaits further
studies.
The in vivo role of ANCA in NCGN
The in vivo potential of ANCA to aggravate the inflammatory
response has recently been demonstrated by Kobayashi, Shi-
bata and Sugisaki [132]. They injected rats with rabbit anti-rat
MPO antibodies together with rabbit anti-rat GBM antibodies.
Control rats were injected with either anti-rat GBM or anti-rat
MPO antibodies. In the latter group no lesions were apparent.
The most severe lesions were found in rats injected with both
antibodies. In this group, MPO was found along the glomerular
capillary wall and anti-MPO could be eluted from the kidneys.
Thus, besides direct activation of rat neutrophils by anti-MPO,
MPO released from activated neutrophils may have bound to
the GBM due to charge interaction followed by in situ binding
of anti-MPO. This local immune complex formation may have
aggravated the passive anti-GBM nephritis. In line with these
findings are the data of Brouwer et al [133]. They immunized
.r
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Fig. 2. Light microscopy of lesions found in
Brown Norway rats immunized with
myeloperoxidase and perfused with a
lysosomal enzyme extract and H202. Crescent
formation, tuft necrosis, and periglomerular
infiltration (x 560).
Brown Norway (BN) rats with human MPO. The rats devel-
oped anti-human MPO antibodies, which, in part, showed
cross-reactivity with rat MPO, as well as delayed type hyper-
sensitivity to human MPO. Five weeks after immunization the
left kidney was perfused with products of activated neutrophils,
that is, lytic enzymes, particularly proteinase 3 and elastase,
MPO, and its substrate H202. The rats developed NCGN with
interstitial infiltrate and vasculitis (Fig. 2). Whereas MPO, IgG,
and C3 could be detected at 24 hours after perfusion along the
GBM, immune deposits were generally absent at 4 and 10 days
after perfusion, which illustrates the pauci-immune character of
the lesions. In control immunized animals perfused with en-
zymes and H202 no significant lesions occurred. When MPO-
immunized rats were perfused with MPO and H202 only, more
or less comparable lesions developed, but those lesions were
accompanied by immune deposits persisting for a longer time
along the GBM. From these findings it is suggested that the
initial step in the development of NCGN is (focal) immune
complex formation. The presence of lytic enzymes, which were
concomitantly perfused but may also have been released from
neutrophils activated by ANCA, probably is responsible for the
degradation of the immune deposits that were detected in the
very early stage of the lesions. Yang et al very recently have
tried to repeat the experiments of Brouwer et al in both BN rats
and spontaneously hypertensive rats [134]. In the latter rats
more severe lesions were found demonstrating the additive
effects of hypertension. In contrast to Brouwer et al [133] they
observed persistence, up to 10 days after perfusion, of immune
deposits along the GBM in both rat strains. Differences both in
the immunization procedure resulting in different qualities of
the antibodies as well as in the composition of the perfusate
may explain the discrepancies between both studies.
Anti-MPO antibodies have also been demonstrated in BN
rats treated with mercuric chloride [531. These rats develop a
polyclonal autoimmune response comprising, among others,
antibodies to MPO. Necrotizing vasculitis, particularly involv-
ing the gut, developed in some of the animals, possibly in
conjunction with a microbial infection [135]. The pathophysio-
logical role of anti-MPO in the induction of the vasculitic
process is, however, not clear in this particular model. A
schematic representation of the possible pathophysiology of
ANCA-associated necrotizing vasculitis/glomerulonephritis
which summarizes the items discussed before is shown in
Figure 3.
Impact of ANCA on treatment
Untreated, the outcome of the systemic necrotizing vasculi-
tides is poor. High doses of corticosteroids have improved
prognosis. Although treatment with steroids alone seems to be
sufficient in less severe forms of polyarteritis nodosa and Churg
Strauss syndrome, many cases of systemic vasculitis treated
with corticosteroids alone still progress to renal failure or show
a fatal outcome. In WG, for instance, corticosteroids have
improved the average survival time from 5 to 12.5 months only.
The introduction of cyclophosphamide [136, 137] has been a
major advance in the treatment of the necrotizing vasculitides
resulting in complete remission in 14 out of 17 patients with
severe vasculitis [136] and 79 out of 85 patients with WG [137].
At present, the usual regimen consists of 2 mg/kg/day cyclo-
phosphamide given orally in combination with 1 mg/kg/day
prednisolone. Since a considerable number of patients relapse
during tapering of immunosuppressives, long-term treatment (1
to 2 years of cyclophosphamide) has been advocated by the
NIH group. Conversion to azathioprin after 8 to 12 weeks [138]
might result in a higher relapse rate although comparitive
studies are not available. A major drawback of long-term
cyclophosphamide treatment is the occurrence of severe ad-
verse effects, in particular opportunistic infections [139] and
bladder toxicity, that is, hemorrhagic cystitis and carcinoma
[140]. In lupus nephritis, the frequency of adverse effects seems
to be reduced without loss of efficacy by using intravenous
pulse cyclophosphamide instead of oral cyclophosphamide
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Fig. 3. Schematic representation of the possible pathophysiology of ANCA -associated necrotizing vasculitis/glomerulonephritis. 1. Neutrophils
(PMN) are primed by low concentrations of cytokines resulting from (local) infection. 2. Primed PMN are further activated by IgG-ANCA to the
production of reactive oxygen species (ROS) and the release of lytic enzymes such as proteinase 3 (Pr3) and elastase (HLE). 3. Products of
activated PMN induce necrotizing inflammation which might be potentiated by the inhibition by ANCA of the a1-antitrypsin (a1AT) induced
inactivation of Pr3. 4. CD4-positive T-cells, possibly autoreactive to Pr3, may contribute to granuloma formation. 5. Activated PMN may damage
endothelial cells to which they adhere as a result of (focal) up-regulation of adhesion molecules. 6. Binding of cationic MPO to polyanionic
(basement) membranes is followed by in situ immune complex formation; attracted PMN additionally activated by ANCA evoke the initial step
of vasculitis/glomerulonephritis and degrade immune complexes.
[141]. In WG, the NIH group described a less favorable systemic vasculitis including WG, Falk et al [143], however,
therapeutic effect of intravenous pulse compared to oral cyclo- found no differences in renal or patient survival between both
phosphamide [142]. In ANCA-positive glomerulonephritis and regimens. A controlled study from the UK also showed that
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pulse and oral cyclophosphamide are equally effective in induc-
ing remission in patients with systemic vasculitis [144].
Based on new insights, in part derived from the detection of
ANCA, into the possible pathophysiology of the systemic
vasculitides, different treatment modalities have been proposed
for ANCA-associated glomerulonephritis and systemic vasculi-
tis.
(a) A number of uncontrolled studies have described a
favorable effect of trimethoprim/sulfamethoxazole (TIS) in the
treatment of WG [145], particularly in limited WG. A prospec-
tive study in 17 patients with limited WG recently showed a
response rate of 65% [146]. In generalized WG the use of T/S
was accompanied by maintenance of remission in 14 out of 32
patients (44%) during a three year period [146]. Prospective
controlled studies are, however, not available. The possibly
positive effect of T/S might be explained by the observation that
relapses of WG are frequently preceeded by infections [1471.
Our group recently found that chronic nasal carriage of Staph-
ylococcus aureus is frequent in patients with WG, occurring in
36 out of 57 patients (63%), and identifies a subgroup more
prone to relapses of the disease. During a 31/2 year period 21 of
the chronic carriers relapsed, compared to 2 out of 21 who were
not considered chronic carriers [81]. Also, chronic nasal carri-
ers had an increased risk of being persistently or intermittently
positive for ANCA [81]. The inter-relationship between chronic
nasal carriage of Staphylococcus aureus and prevention of
relapses by TIS treatment has not been studied so far. Although
the efficacy of T/S needs to be substantiated, this mode of
treatment may be particularly useful in the management of
chronic inflammation and superimposed infections of nose and
sinuses in patients with WG.
(b) Several newly proposed treatment modalities in systemic
vasculitis are based on the assumption that ANCA play a
critical role in the pathophysiology of the disease. As stated
before, rises of c-ANCA titers seem to preceed the develop-
ment of relapses of WG [161. Based on these findings a
controlled prospective study was performed in which patients
were assigned to treatment or no treatment once a significant
rise of ANCA had occurred [78]. Treatment based on rises of
ANCA titer appeared to prevent relapses of WG in this study on
a small number of patients. These data have to be confirmed by
studies on larger groups of patients.
Plasma exchange (PE) has been proposed as a direct ap-
proach to remove pathogenic autoantibodies. A controlled
study on the additional role of PE in the initial treatment of
patients with necrotizing glomerulonephntis without anti-GBM
antibodies was published in 1991 [1481. Included were patients
with impaired renal function, crescentic necrotizing glomerulo-
nephritis in the biopsy, and a clinical diagnosis of WG, MPA, or
idiopathic rapidly progressive glomerulonephritis. Data on
ANCA were not consistently available. Forty-eight cases could
be analyzed of whom 23 were treated with immunosuppressives
only and 25 with additional PE. Only in patients who were
dialysis-dependent at presentation (N = 19) was an additional
benefit of PE observed: 10 out of 11 patients treated with
additional PE recovered from renal failure, whereas only 3
patients recovered out of 8 patients treated with immunosup-
pressives alone. A comparable beneficial effect has been found
for the additional use of pulse methyiprednisolone in patients
with rapidly progressive glomerulonephntis and crescentic gb-
merulonephritis who were dialysis-dependent at presentation
[149]. Thus, either PE or pulse methyiprednisolone can be
added to the oral regimen described before in patients with
ANCA-associated vasculitis/glomerulonephritis who present
with acute renal failure.
Intravenous gammaglobulin (IVIg) therapy has been tried in
an increasing number of autoimmune diseases. Originally used
in autoimmune thrombocytopenia in order to block or saturate
Fc-receptor mediated clearance of antibody-coated platelets,
IVIg might also exert its effect by the presence in the prepara-
tion of anti-idiotypic antibodies which interact with the idio-
typic network. Anti-idiotypic antibodies reactive to ANCA
have, indeed, been detected in pooled human immunoglobulin
and in the sera from patients with ANCA-positive vasculitis
drawn during remission [150]. Preliminary data suggest that
IVIg infused at 0.4 g/kglday on five consecutive days may have
a beneficial effect in patients with ANCA-positive vasculitis
resulting not only in clinical improvement but also in some 50%
reduction in levels of ANCA [151]. Controlled prospective
studies are, however, needed to demonstrate the clinical use-
fulness of IVIg.
(c) Inflammatory lesions of lung and kidney in WG are
characterized by large mononuclear infiltrates containing mono-
cytes and T cells, with a majority of CD4-positive cells [125,
1261. The antigenic specificities of those T cells are not known,
but peripheral blood lymphocytes reactive to ANCA-antigens
such as proteinase 3 and MPO have been described [129—131].
In a patient with long-standing unclassified vasculitis treatment
with the combination of two monoclonal antibodies, one di-
rected against an antigen present on all mononuclear cells
(CDw52) and the other against the CD4 molecule, resulted in
long-lasting clinical remission whereas injection of the first
antibody alone induced a short-lived remission only [152].
Recently, two additional patients with microscopic polyarteritis
unresponsive to conventional treatment were treated with a
comparable regimen [153]. Long-lasting remission was reached
in one patient, the other developed antibodies to the humanized
anti-CDwS2 monoclonal antibody. These pilot studies await
confirmation from a larger scale controlled study.
Conclusion
The diagnostic potential of ANCA is now fairly well estab-
lished for the target antigens proteinase 3 and MPO. The
presence of anti-proteinase 3 strongly suggests a diagnosis of
Wegener's granulomatosis (WG), either in its generalized or
limited presentation, although the association is not absolute.
Changes in levels of anti-proteinase 3 in WG generally reflect
disease activity. Anti-MPO is associated with various forms of
necrotizing vasculitis including idiopathic necrotizing and cres-
centic glomerubonephritis (NCGN). Anti-MPO also occurs,
incidentally, in other diseases. The diagnostic significance of
ANCA of other or still unknown specificities has not yet been
definitely established.
The pathophysiological role of ANCA has been studied in in
vitro and in vivo models. In vitro anti-proteinase 3 interferes
with the inactivation of proteinase 3 by a1-antitrypsin. ANCA
of diverse specificities are able to activate primed neutrophils to
the production of reactive oxygen species and the release of
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lysosomal enzymes. Both effects may contribute to the inflam-
matory process. With respect to vasculitis and glomerulone-
phntis the possible expression of proteinase 3 at the surface of
(activated) endothelial cells and the binding of MPO on these
cells might allow the respective antibodies to react to their
targets in vivo and to injure the endothelium. In MPO-immu-
nized animals perfusion of the kidney with the products of
activated neutrophils results in the development of pauci-
immune NCGN.
Although many questions still remain, the expanding knowl-
edge on ANCA has greatly contributed to the diagnosis and the
understanding of the pauci-immune necrotizing vasculitides.
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